<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81477</article-id><article-id pub-id-type="doi">10.7554/eLife.81477</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-295273"><name><surname>Gálvez</surname><given-names>Nicolas M S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287175"><name><surname>Pacheco</surname><given-names>Gaspar A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5748-5027</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287176"><name><surname>Schultz</surname><given-names>Barbara M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287177"><name><surname>Melo-González</surname><given-names>Felipe</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-149653"><name><surname>Soto</surname><given-names>Jorge A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287178"><name><surname>Duarte</surname><given-names>Luisa F</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287179"><name><surname>Gonzalez</surname><given-names>Liliana A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-189450"><name><surname>Rivera</surname><given-names>Daniela S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-149659"><name><surname>Ríos</surname><given-names>Mariana</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287180"><name><surname>Berrios</surname><given-names>Roslye V</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-295271"><name><surname>Vázquez</surname><given-names>Yaneisi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287182"><name><surname>Moreno-Tapia</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287183"><name><surname>Vallejos</surname><given-names>Omar P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287184"><name><surname>Andrade</surname><given-names>Catalina A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287185"><name><surname>Hoppe-Elsholz</surname><given-names>Guillermo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287186"><name><surname>Iturriaga</surname><given-names>Carolina</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287187"><name><surname>Urzua</surname><given-names>Marcela</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287188"><name><surname>Navarrete</surname><given-names>María S</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287189"><name><surname>Rojas</surname><given-names>Álvaro</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287190"><name><surname>Fasce</surname><given-names>Rodrigo</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-295272"><name><surname>Fernández</surname><given-names>Jorge</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287192"><name><surname>Mora</surname><given-names>Judith</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287193"><name><surname>Ramirez</surname><given-names>Eugenio</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287194"><name><surname>Gaete-Argel</surname><given-names>Aracelly</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287195"><name><surname>Acevedo</surname><given-names>Mónica</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287196"><name><surname>Valiente-Echeverria</surname><given-names>Fernando</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287197"><name><surname>Soto-Rifo</surname><given-names>Ricardo</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-132478"><name><surname>Weiskopf</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-231334"><name><surname>Grifoni</surname><given-names>Alba</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-208165"><name><surname>Sette</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-287198"><name><surname>Zeng</surname><given-names>Gang</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-287199"><name><surname>Meng</surname><given-names>Weining</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-287200"><name><surname>Gonzalez-Aramundiz</surname><given-names>José V</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294128"><name><surname>Johnson</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82704"><name><surname>Goldblatt</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-23652"><name><surname>González</surname><given-names>Pablo A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7709-6870</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" id="author-287201"><name><surname>Abarca</surname><given-names>Katia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-287202"><name><surname>Bueno</surname><given-names>Susan M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf9"/></contrib><contrib contrib-type="author" corresp="yes" id="author-149329"><name><surname>Kalergis</surname><given-names>Alexis M</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7622-5263</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf10"/></contrib><aff id="aff1"><institution content-type="dept">Departamento de Genética Molecular y Microbiología</institution>, <institution>Pontificia Universidad Católica de Chile</institution>, <addr-line><named-content content-type="city">Santiago</named-content></addr-line>, <country>Chile</country></aff><aff id="aff2"><institution content-type="dept">Departamento de Enfermedades Infecciosas e Inmunología Pediátrica</institution>, <institution>Pontificia Universidad Católica de Chile</institution>, <addr-line><named-content content-type="city">Santiago</named-content></addr-line>, <country>Chile</country></aff><aff id="aff3"><institution content-type="dept">Departamento de Enfermedades Infecciosas del Adulto</institution>, <institution>Pontificia Universidad Católica de Chile</institution>, <addr-line><named-content content-type="city">Santiago</named-content></addr-line>, <country>Chile</country></aff><aff id="aff4"><institution content-type="dept">Departamento de Laboratorio Biomédico</institution>, <institution>Instituto de Salud Pública de Chile</institution>, <addr-line><named-content content-type="city">Santiago</named-content></addr-line>, <country>Chile</country></aff><aff id="aff5"><institution content-type="dept">Laboratory of Molecular and Cellular Virology</institution>, <institution>University of Chile</institution>, <addr-line><named-content content-type="city">Santiago</named-content></addr-line>, <country>Chile</country></aff><aff id="aff6"><institution content-type="dept">Center for Infectious Disease and Vaccine Research</institution>, <institution>La Jolla Institute For Allergy &amp; Immunology</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country></aff><aff id="aff7"><institution content-type="dept">Department of Medicine</institution>, <institution>University of California, San Diego</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country></aff><aff id="aff8"><institution>Sinovac Biotech</institution>, <addr-line><named-content content-type="city">Beijing</named-content></addr-line>, <country>China</country></aff><aff id="aff9"><institution content-type="dept">Departamento de Farmacia</institution>, <institution>Pontificia Universidad Católica de Chile</institution>, <addr-line><named-content content-type="city">Santiago</named-content></addr-line>, <country>Chile</country></aff><aff id="aff10"><institution content-type="dept">Department of Infection</institution>, <institution>University College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-190571"><name><surname>Iqbal</surname><given-names>Jameel</given-names></name><role>Reviewing editor</role><aff><institution>DaVita Labs</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>sbueno@bio.puc.cl</email> (SB);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>akalergis@bio.puc.cl</email> (AK);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>13</day><month>10</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e81477</elocation-id><history><date date-type="received"><day>29</day><month>06</month><year>2022</year></date><date date-type="accepted"><day>09</day><month>10</month><year>2022</year></date></history><permissions><copyright-statement>© 2022, Gálvez et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Gálvez et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81477-v1.pdf"/><abstract><p><bold>Background:</bold> The development of vaccines to control the COVID-19 pandemic progression is a worldwide priority. CoronaVac<sup>®</sup> is an inactivated SARS-CoV-2 vaccine approved for emergency use with robust efficacy and immunogenicity data reported in trials in China, Brazil, Indonesia, Turkey, and Chile.</p><p><bold>Methods:</bold> This study is a randomized, multicenter, and controlled phase 3 trial in healthy Chilean adults aged ≥18 years. Volunteers received two doses of CoronaVac<sup>®</sup> separated by two (0-14 schedule) or four weeks (0-28 schedule). 2,302 volunteers were enrolled, 440 were part of the immunogenicity arm, and blood samples were obtained at different times. Samples from a single center are reported. Humoral immune responses were evaluated by measuring the neutralizing capacities of circulating antibodies. Cellular immune responses were assessed by ELISPOT and flow cytometry. Correlation matrixes were performed to evaluate correlations in the data measured.</p><p><bold>Results:</bold> Both schedules exhibited robust neutralizing capacities with the response induced by the 0-28 schedule being better. No differences were found in the concentration of antibodies against the virus and different variants of concern between schedules. Stimulation of PBMCs with MPs induced the secretion of IFN-g and the expression of activation induced markers for both schedules. Correlation matrixes showed strong correlations between neutralizing antibodies and IFN-g secretion.</p><p><bold>Conclusions:</bold> Immunization with CoronaVac<sup>®</sup> in Chilean adults promotes robust cellular and humoral immune responses. The 0-28 schedule induced a stronger humoral immune response than the 0-14 schedule.</p><p><bold>Funding:</bold> Ministry of Health, Government of Chile, Confederation of Production and Commerce &amp; Millennium Institute on Immunology and Immunotherapy, Chile.</p><p><bold>Clinical trial number:</bold> NCT04651790.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>Ministry of Health, Government of Chile</institution></institution-wrap></funding-source><award-id>N/A</award-id><principal-award-recipient><name><surname>Kalergis</surname><given-names>Alexis M</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>The Confederation of Production and Commerce, Chile</institution></institution-wrap></funding-source><award-id>N/A</award-id><principal-award-recipient><name><surname>Kalergis</surname><given-names>Alexis M</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>The Millenium Institute in Immunology and Immunotherapy</institution></institution-wrap></funding-source><award-id>ICN09_016</award-id><principal-award-recipient><name><surname>González</surname><given-names>Pablo A</given-names></name><name><surname>Bueno</surname><given-names>Susan M</given-names></name><name><surname>Kalergis</surname><given-names>Alexis M</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>The Innovation fund for competitiveness FIC-R 2017</institution></institution-wrap></funding-source><award-id>30488811-0</award-id><principal-award-recipient><name><surname>González</surname><given-names>Pablo A</given-names></name><name><surname>Bueno</surname><given-names>Susan M</given-names></name><name><surname>Kalergis</surname><given-names>Alexis M</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>FONDECYT Grant</institution></institution-wrap></funding-source><award-id>1190156</award-id><principal-award-recipient><name><surname>Soto-Rifo</surname><given-names>Ricardo</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>FONDECYT Grant</institution></institution-wrap></funding-source><award-id>1180798</award-id><principal-award-recipient><name><surname>Valiente-Echeverria</surname><given-names>Fernando</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution>NIH NIAID Contract</institution></institution-wrap></funding-source><award-id>75N93021C00016</award-id><principal-award-recipient><name><surname>Sette</surname><given-names>Alessandro</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution>NIH NIAID Contract</institution></institution-wrap></funding-source><award-id>75N9301900065</award-id><principal-award-recipient><name><surname>Weiskopf</surname><given-names>Daniela</given-names></name><name><surname>Sette</surname><given-names>Alessandro</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Ricardo Soto-Rifo, has received funding from ANID - ICM, ICN 2021_045. The author has no other competing interests to declare.</p></fn><fn fn-type="conflict" id="conf3"><p>Daniela Weiskopf, has received funding support from the NIH under contract number 75N93019C00065. The Jolla Institute for Immunology (LJI) has filed for patent protection for various aspects of T cell epitope and vaccine design work. The author has no other competing interests to declare.</p></fn><fn fn-type="conflict" id="conf4"><p>Alba Grifoni, Alba Grifoni has received funding support from the NIH under contract number 75N93021C00016. The Jolla Institute for Immunology (LJI) has filed for patent protection for various aspects of T cell epitope and vaccine design work. The author has no other competing interests to declare.</p></fn><fn fn-type="conflict" id="conf5"><p>Alessandro Sette, is a consultant for Gritstone Bio, Flow Pharma, Arcturus, Immunoscape, CellCarta, Moderna, AstraZeneca, Fortress, Repertoire, Gilead, Gerson Lehrman Group, RiverVest, MedaCorp, Guggenheim, OxfordImmunotech, and Avalia. The author has received funding support from the NIH under contract 75N93021C00016. The Jolla Institute for Immunology (LJI) has filed for patent protection for various aspects of T cell epitope and vaccine design work. The author has no other competing interests to declare.</p></fn><fn fn-type="conflict" id="conf6"><p>Gang Zeng, is a SINOVAC employee and contributed to the conceptualization of the study (clinical protocol and eCRF design)..</p></fn><fn fn-type="conflict" id="conf7"><p>Weining Meng, is a SINOVAC employee and contributed to the conceptualization of the study (clinical protocol and eCRF design)..</p></fn><fn fn-type="conflict" id="conf8"><p>Pablo A González, acts as the Executive Director of the clinical trials PedCoronaVac03CL clinical study (ClinicalTrials.gov NCT04992260) and CoronaVac03CL (ClinicalTrials.govNCT04651790) (funds to the institution), and receives research support from Millennium Institute on Immunology and Immunotherapy. The author received funding from Agencia Nacional de Investigación y Desarrollo, Fondo de Fomento al Desarrollo Científico y tecnológico. The author has no other competing interests to declare.</p></fn><fn fn-type="conflict" id="conf9"><p>Susan M Bueno, acts as the Scientific Director of clinical trials PedCoronaVac03CL clinical study (ClinicalTrials.gov NCT04992260) and CoronaVac03CL (ClinicalTrials.govNCT04651790) (funds to the institution), and receives research support from Millennium Institute on Immunology and Immunotherapy. The author has received funding from Agencia Nacional de Invetsigación y Desarrollo, Fondo de Fomento al Desarrollo Científico y tecnológico ID20I10082. The author has no other competing interests to declare.</p></fn><fn fn-type="conflict" id="conf10"><p>Alexis M Kalergis, acts as the General Director of clinical trials PedCoronaVac03CL clinical study (ClinicalTrials.gov NCT04992260) and CoronaVac03CL (ClinicalTrials.govNCT04651790). The author has received funding from Agencia Nacional de Investigación y Desarrollo (ANID) - Millennium Science Initiative Program - ICN09_016 / ICN 2021_045: Millennium Institute on Immunology and Immunotherapy (ICN09_016 / ICN 2021_045; former P09/016-F) and Agencia Nacional de Investigación y Desarrollo [FONDECYT grant numbers 1190830. The author has no other competing interests to declare.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: This clinical trial (clinicaltrials.gov NCT04651790) is a randomized and controlled study held in Chile with eight different sites. The study protocol adhered to the current Tripartite Guidelines for Good Clinical Practices, the Declaration of Helsinki, and local regulations and was approved by the Institutional Scientific Ethical Committee of Health Sciences of the Pontificia Universidad Católica de Chile, (#200708006). The execution was approved by the Chilean Public Health Institute (#24204/20).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All raw data (anonymized to protect the information of volunteers) is included with the publication of this article as a supporting file. Source Data File 1 contains the numerical data used to generate all the figures.The study protocol is also available online and was previously published in doi: 10.1101/2021.03.31.21254494.</p></sec><supplementary-material><ext-link xlink:href="elife-81477-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>